OCUL
Ocular Therapeutix, Inc.
Nasdaq · usd
Ocular Therapeutix, Inc. (OCUL) trades at $6.68 (-2.48%) as of 12:48:38 PM EST on Nov 10, 2026, -12.17% over the past month. Market cap is $1.51B, with 8.1 days to cover in short interest.
Stock performance
How Ocular Therapeutix, Inc. (OCUL) stock has performed from one day to one year, with its 52-week range.
- 1D
- -3.07%
- 1W
- -2.64%
- 1M
- -12.17%
- YTD
- -45.30%
- 1Y
- -40.82%
- 52-wk range
- $6.00 – $16.44
Key statistics
Today's trading snapshot for OCUL: day range, open, previous close, volume and market cap.
- Day range
- $6.60 – $6.87
- Open
- $6.86
- Prev close
- $6.85
- Volume
- 1.03M
- Market cap
- $1.51B
- Shares out
- 219.62M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Ocular Therapeutix, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 28.94
- P/B
- 2.90
- P/FCF
- —
- ROE
- -58.0%
- ROA
- -44.9%
- Debt/Equity
- 0.14
- Div yield
- 0.00%
As of Nov 9, 2026
8-K filings
Material corporate events Ocular Therapeutix, Inc. has disclosed to the SEC on Form 8-K.
- Director departureNov 9, 2026
On November 6, 2026, Seung Suh Hong, Ph.D., notified the Company of his resignation from the Board, effective December 31, 2026. Dr. Hong's resignation is not the result of any disagreement with the Board or with management on any matter relating to the Company's operations, policies or practices.
- Quarterly earningsNov 9, 2026
On November 9, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
- Executive officer departureOct 16, 2026
On October 14, 2026, Sanjay Nayak, M.B.B.S., Ph.D., Chief Strategy Officer of Ocular Therapeutix, Inc. (the "Company"), notified the Company of his resignation from the Company, effective October 16, 2026, to become the Chief Executive Officer of a privately-held company.
- Executive compensation changeJun 12, 2026
Additionally, the Company granted Mr. Robins, effective June 10, 2026 (the 'Grant Date'), (i) a stock option to purchase up to 14,024 shares of the Company's common stock at a per share exercise price equal to the closing price of the Company's common stock on The Nasdaq Global Market on the Grant Date and (ii) a restricted stock unit award representing the right to receive 15,441 shares of the Company's common stock. Subject to Mr. Robins' continued service to the Company, his option award vests in equal monthly installments over a four-year period, and his restricted stock unit award vests in equal yearly installments over a three-year period.
- Investor presentationFeb 27, 2026
Ocular Therapeutix, Inc. (the "Company") will make available under the Investors section of its corporate website the slides to be presented by the Company at the 49th Macula Society Annual Meeting on February 27, 2026
OCUL short interest
How heavily OCUL is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.1
- Short interest
- 28.76M
- Avg volume
- 3.55M
As of · reported to FINRA twice monthly.
OCUL news
The latest news and headlines about Ocular Therapeutix, Inc. (OCUL).
- Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesnegativeZacks Investment Research· Nov 9, 2026
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)neutralGlobeNewswire Inc.· Nov 6, 2026
- Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass EstimatespositiveZacks Investment Research· Nov 3, 2026
- Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in DevelopmentpositiveGlobeNewswire Inc.· Jul 3, 2026
- Ocular Therapeutix™ to Participate in July Scientific and Investor ConferencespositiveGlobeNewswire Inc.· Jul 1, 2026
Frequently asked questions
What is the Ocular Therapeutix, Inc. (OCUL) stock price today?
Ocular Therapeutix, Inc. (OCUL) is trading at $6.68 (-2.48% on the day) as of 12:48:38 PM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Ocular Therapeutix, Inc.?
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye.
What is the short interest in OCUL?
As of Oct 15, 2026, OCUL has 28.76M shares short and 8.1 days to cover.
What exchange is OCUL listed on?
Ocular Therapeutix, Inc. (OCUL) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of OCUL with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a OCUL analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.